Novel Series of Benzothiazole-Based Pyrazolidinediones Targeting PPARγ. In Silico Studies, Synthesis and In Vivo Anti-Diabetic Activity.
暂无分享,去创建一个
[1] Eric Valeur,et al. Emerging modes-of-action in drug discovery. , 2019, MedChemComm.
[2] M. Haroun. Novel Hybrids of Pyrazolidinedione and Benzothiazole as TZD Analogues. Rationale Design, Synthesis and In Vivo Anti-Diabetic Evaluation. , 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).
[3] S. Shorte,et al. Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases. , 2019, Trends in parasitology.
[4] S. Shima,et al. Protein crystal structure determination with the crystallophore, a nucleating and phasing agent , 2019, Journal of applied crystallography.
[5] Sangdun Choi,et al. A Structure-Based Drug Discovery Paradigm , 2019, International journal of molecular sciences.
[6] A. Husain,et al. Novel hybrids of benzothiazole-1,3,4-oxadiazole-4-thiazolidinone: Synthesis, in silico ADME study, molecular docking and in vivo anti-diabetic assessment. , 2019, Bioorganic chemistry.
[7] A. Schiedel,et al. A Complete Assessment of Dopamine Receptor- Ligand Interactions through Computational Methods , 2019, Molecules.
[8] C. Pheiffer,et al. Corrigendum: Blood-Based DNA Methylation Biomarkers for Type 2 Diabetes: Potential for Clinical Applications , 2019, Front. Endocrinol..
[9] Ashley L Cole,et al. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. , 2019, Journal of managed care & specialty pharmacy.
[10] F. Ismail-Beigi,et al. Prolonged Exposure to Insulin Inactivates Akt and Erk1/2 and Increases Pancreatic Islet and INS1E β-Cell Apoptosis , 2018, Journal of the Endocrine Society.
[11] R. Sreenivasulu,et al. Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs , 2018, Letters in Drug Design & Discovery.
[12] Hideki Yamamoto,et al. Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification. , 2018, Bioorganic & medicinal chemistry.
[13] R. de Caterina,et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs , 2018, Nature Reviews Cardiology.
[14] T. Nero,et al. Protein structure and computational drug discovery. , 2018, Biochemical Society transactions.
[15] A. Geronikaki,et al. 5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation. , 2018, Bioorganic & medicinal chemistry.
[16] Yonggong Zhai,et al. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development , 2018, International journal of molecular sciences.
[17] A. Manilal,et al. Effective synthesis of some novel pyrazolidine-3,5-dione derivatives via Mg(II) catalyzed in water medium and their anticancer and antimicrobial activities , 2018, Molecular Diversity.
[18] V. Mohan,et al. Dietary and nutritional approaches for prevention and management of type 2 diabetes , 2018, British Medical Journal.
[19] B. Chew,et al. Psychological interventions for behavioral adjustments in diabetes care – a value-based approach to disease control , 2018, Psychology research and behavior management.
[20] R. Kant,et al. Synthesis, molecular modelling studies and ADME prediction of benzothiazole clubbed oxadiazole-Mannich bases, and evaluation of their anti-diabetic activity through in vivo model. , 2018, Bioorganic chemistry.
[21] M. Amir,et al. Design, Synthesis, and Screening of Hybrid Benzothiazolyl-Oxadiazoles as Anticonvulsant Agents , 2018 .
[22] Sun Choi,et al. Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. , 2018, Journal of medicinal chemistry.
[23] S. Suh,et al. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ , 2018, Scientific Reports.
[24] Y. Im,et al. Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs , 2017, Scientific Reports.
[25] Manisha Pandey,et al. An update on natural compounds in the remedy of diabetes mellitus: A systematic review , 2017, Journal of traditional and complementary medicine.
[26] Nikolai Petrovsky,et al. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs. , 2017, Biochimica et biophysica acta. General subjects.
[27] Hans-Joachim Wittmann,et al. Binding Kinetics and Pathways of Ligands to GPCRs. , 2017, Trends in pharmacological sciences.
[28] C. Cohrs,et al. Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis , 2017, Molecular metabolism.
[29] V. Mohan,et al. Type 2 Diabetes: Demystifying the Global Epidemic , 2017, Diabetes.
[30] Inês Barroso,et al. Prospective functional classification of all possible missense variants in PPARG , 2016, Nature Genetics.
[31] A. Chawla,et al. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? , 2016, Indian journal of endocrinology and metabolism.
[32] A. Saxena,et al. Design, synthesis and biological evaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]triazol-6(5H)ones. Pharmacophore models for antifungal activity , 2016 .
[33] J. Mendieta-Wejebe,et al. Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones , 2016, PPAR research.
[34] Stefano Moro,et al. Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations , 2016, J. Chem. Inf. Model..
[35] W. Han,et al. Pancreatic regulation of glucose homeostasis , 2016, Experimental & Molecular Medicine.
[36] Wen-en Zhao,et al. Synthesis, in vitro and in vivo anticancer activities of novel 4-substituted 1,2-bis(4-chlorophenyl)-pyrazolidine-3,5-dione derivatives , 2015 .
[37] H. Miyachi,et al. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations. , 2015, Bioorganic & medicinal chemistry letters.
[38] B. Geng,et al. Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance. , 2015, Metabolism: clinical and experimental.
[39] A. Ahmadi,et al. Synthesis and blood glucose and lipid-lowering effects of benzothiazole-substituted benzenesulfonylurea derivatives , 2015, Monatshefte für Chemie - Chemical Monthly.
[40] M. Mulero,et al. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage. , 2015, Journal of medicinal chemistry.
[41] N. Desai,et al. Thiazolidinedione compounds: a patent review (2010 – present) , 2015, Expert opinion on therapeutic patents.
[42] W. Zou,et al. An Insulin‐Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] M. Makishima,et al. Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists based on the helix12-folding inhibition hypothesis. , 2015, European journal of medicinal chemistry.
[44] B. Chew,et al. Psychological aspects of diabetes care: Effecting behavioral change in patients. , 2014, World journal of diabetes.
[45] M. Lazar,et al. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.
[46] Martin Bopst,et al. Minireview: Challenges and opportunities in development of PPAR agonists. , 2014, Molecular endocrinology.
[47] P. Yogeeswari,et al. Investigating structure-activity relationship and mechanism of action of antitubercular 1-(4-chlorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrobenzylidene) pyrazolidine-3,5-dione [CD59]. , 2014, International journal of mycobacteriology.
[48] C. Tratrat,et al. Molecular modelling design, synthesis and cytotoxic evaluation of certain substituted 2-(3,4,5-triacetoxybenzoylamino)benzo[d]thiazole and 2-(galloylamino)benzo[d]thiazole derivatives having potential topoisomerase-I inhibitory activity , 2013, Journal of enzyme inhibition and medicinal chemistry.
[49] Kenji Matsuno,et al. Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility. , 2013, Bioorganic & medicinal chemistry.
[50] Yang Zhang,et al. Protein structure prediction. , 2012, International journal of modern physics. B.
[51] E. Dorsey,et al. Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review , 2012, Medical care.
[52] R. Wadwa,et al. Hypoglycemia, diabetes, and cardiovascular disease. , 2012, Diabetes technology & therapeutics.
[53] Paulo C. T. Souza,et al. GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain , 2012, The Journal of Biological Chemistry.
[54] S. Nath,et al. Synthesis and Antidiabetic Evaluation of Benzothiazole Derivatives , 2012 .
[55] Philippe Chavatte,et al. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. , 2012, Journal of medicinal chemistry.
[56] Kuo-Chen Chou,et al. Insights into the Mutation-Induced HHH Syndrome from Modeling Human Mitochondrial Ornithine Transporter-1 , 2012, PloS one.
[57] M. J. Chalmers,et al. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism. , 2012, Structure.
[58] K. Chou,et al. Novel Inhibitor Design for Hemagglutinin against H1N1 Influenza Virus by Core Hopping Method , 2011, PloS one.
[59] A. Ammazzalorso,et al. Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists. , 2011, Bioorganic & medicinal chemistry letters.
[60] Sriparna Datta,et al. Design, synthesis and antidiabetic evaluation of oxazolone derivatives , 2011 .
[61] Kuo-Chen Chou,et al. Insights from Modeling the 3D Structure of New Delhi Metallo-β-Lactamse and Its Binding Interactions with Antibiotic Drugs , 2011, PloS one.
[62] Daniel Jones,et al. Potential remains for PPAR-targeted drugs , 2010, Nature Reviews Drug Discovery.
[63] J. Deschamps. X-ray crystallography of chemical compounds. , 2010, Life sciences.
[64] Yang Li,et al. Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma. , 2009, Bioorganic & medicinal chemistry letters.
[65] J. Chou,et al. Mechanism of drug inhibition and drug resistance of influenza A M2 channel , 2009, Proceedings of the National Academy of Sciences.
[66] John E. Johnson,et al. Synergy of NMR, computation, and X-ray crystallography for structural biology. , 2009, Structure.
[67] M. Lindstrom,et al. INT131: A Selective Modulator of PPARγ , 2009 .
[68] R. Loddo,et al. In vitro antitumor and antiviral activities of new benzothiazole and 1,3,4-oxadiazole-2-thione derivatives , 2008, Acta pharmaceutica.
[69] M. Lambert,et al. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? , 2008, Current topics in medicinal chemistry.
[70] M. Makishima,et al. Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists. , 2007, Bioorganic & medicinal chemistry letters.
[71] J. Feige,et al. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. , 2007, Biochimica et biophysica acta.
[72] K. Chou,et al. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. , 2007, Biochemical and biophysical research communications.
[73] B. Staels,et al. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis , 2006, Expert opinion on emerging drugs.
[74] Kuo-Chen Chou,et al. Molecular therapeutic target for type-2 diabetes. , 2004, Journal of proteome research.
[75] Kuo-Chen Chou,et al. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS , 2003, Biochemical and Biophysical Research Communications.
[76] Kuo-Chen Chou,et al. Identification of the N‐terminal functional domains of Cdk5 by molecular truncation and computer modeling , 2002, Proteins.
[77] B. Norberg,et al. Pyrazolidine-3,5-dione angiotensin-II receptor antagonists. , 2001, Acta crystallographica. Section C, Crystal structure communications.
[78] Millard H. Lambert,et al. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .
[79] K D Watenpaugh,et al. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. , 1999, Biochemical and biophysical research communications.
[80] W. Lubawy,et al. Anticonvulsant activity of 1-alkyl-4-substituted 3,5-pyrazolidinediones. , 1974, Journal of pharmaceutical sciences.
[81] M. Attimarad,et al. Design, Synthesis, Evaluation of Antimicrobial Activity and Docking Studies of New Thiazole-based Chalcones. , 2019, Current topics in medicinal chemistry.
[82] M. Attimarad,et al. New Benzothiazole-based Thiazolidinones as Potent Antimicrobial Agents. Design, synthesis and Biological Evaluation. , 2018, Current topics in medicinal chemistry.
[83] Alexander D. MacKerell,et al. Computer-Aided Drug Design Methods. , 2017, Methods in molecular biology.
[84] A. Geronikaki,et al. Thiazole-Based Thiazolidinones as Potent Antimicrobial Agents. Design, Synthesis and Biological Evaluation. , 2016, Combinatorial chemistry & high throughput screening.
[85] Anita Singh,et al. Synthesis and antinociceptive activity of novel mannich base derivatives of some new fused 3,5-pyrazolidinedione , 2014, Journal of advanced pharmaceutical technology & research.